Proof-of-concept studies ongoing in lupus nephritis (LN), systemic sclerosis (SSc) and antibody mediated rejection (AMR); topline results expected for LN in fourth quarter of 2025, SSc in second half ...

One of the main factors determining therapeutic antibodies’ half-life is the interaction between the antibody’s Fc region and ...

Immunovant, Inc. (NASDAQ:IMVT) is one of the best oversold NASDAQ stocks to buy now. On July 10, Goldman Sachs analyst ...

Imaavy (Nipocalimab-aahu ), a neonatal Fc receptor (FcRn) blocker, has been approved by the FDA for treatment of generalized myasthenia gravis in adults and adolescents with anti-acetylcholine ...

Using cryo-EM, researchers elucidated the structure of key receptors integral to fast excitatory synaptic transmission in the rat cerebellum.

However, the receptor's low expression levels and instability have long hindered efforts to resolve its structure, leaving questions about how GnRH activates GnRHR unanswered.

Chronic pain affects millions of people in the US. Targeting an oft-overlooked brain receptor could one day offer relief.

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis.

In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in ...

FcRn blockers are medicines that block the Fc receptor. In myasthenia gravis, autoantibodies – antibodies that mistakenly target the body’s own cells and proteins – especially IgG antibodies, attack ...

No-moat Takeda Pharmaceutical is Japan’s leading pharmaceutical company by revenue. While the firm historically focused on the Japan market, management has undertaken an ambitious overhaul to ...